Fin Trust Capital Advisors, LLC Gilead Sciences, Inc. Transaction History
Fin Trust Capital Advisors, LLC
- $525 Million
- Q2 2024
A detailed history of Fin Trust Capital Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Fin Trust Capital Advisors, LLC holds 1,354 shares of GILD stock, worth $113,207. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,354
Previous 1,320
2.58%
Holding current value
$113,207
Previous $96,000
4.17%
% of portfolio
0.02%
Previous 0.02%
Shares
19 transactions
Others Institutions Holding GILD
# of Institutions
1,879Shares Held
1.02BCall Options Held
12MPut Options Held
8.96M-
Black Rock Inc. New York, NY121MShares$10.1 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$9.64 Billion0.15% of portfolio
-
Capital World Investors Los Angeles, CA76.2MShares$6.38 Billion0.88% of portfolio
-
Capital Research Global Investors Los Angeles, CA60.4MShares$5.05 Billion0.94% of portfolio
-
State Street Corp Boston, MA59.3MShares$4.96 Billion0.18% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $105B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...